Introduction: Seminal clinical trials with the triple combination of elexacaftor-tezacaftor-ivacaftor (ETI) demonstrated clinical efficacy in people with cystic fibrosis (pwCF) who carry at least one F508del mutation. However, due to exclusion criteria of these clinical trials, the effect of ETI was not studied in a substantial number of pwCF. Thus, we ran a single center trial to evaluate a clinical efficacy of ETI treatment in adult pwCF who were ineligible for enrollment in registration studies. Methods: PwCF on ETI with prior lumacaftor-ivacaftor therapy, severe airway obstruction, well-preserved lung function, or with airway infection with pathogens at risk of more rapid decline in lung function formed the study group, while all the others on ETI formed the control group. Lung function, nutritional status and sweat chloride concentration were assessed before and after initialization of ETI therapy over a 6-month period. Results: Approximately a half of the ETI-treated pwCF at the adult Prague CF center (49 of 96) were assigned to the study group. Their mean changes in body mass index ( + 1.04 kg/m2) and in sweat chloride concentration (-48.4 mmol/L) were similar to the control group ( + 1.02 kg/m2; -49.7 mmol/L), while the mean change in percent predicted forced expiratory volume in 1 s (ppFEV1; + 10.3 points) was significantly lower than in the control group ( + 15.8 points) (p = 0.0015). In the subgroup analysis, pwCF with severe airway obstruction (ppFEV1 <40) and pwCF with well-preserved lung function (ppFEV1 >90) showed a less potential for improvement in lung function during the ETI treatment than controls (median change in ppFEV1 + 4.9 points and + 9.5 points, respectively). Conclusion: PwCF not eligible for inclusion in clinical trials demonstrated improvement in lung function and nutritional status following the initiation of treatment with the ETI combination. Moderate increase in ppFEV1 was observed in those with severe airway obstruction or well-preserved lung function.

Department of Medical Microbiology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Department of Pneumology 2nd Faculty of Medicine Charles University and Motol University Hospital Prague Czechia

Zobrazit více v PubMed

Barry P. J., Mall M. A., Álvarez A., Colombo C., de Winter-de Groot K. M., Fajac I., et al. (2021). Triple therapy for cystic fibrosis phe508del-gating and -residual function genotypes. N. Engl. J. Med. 385 (9), 815–825. 10.1056/NEJMoa2100665 PubMed DOI PMC

Burgel P. R., Durieu I., Chiron R., Ramel S., Danner-Boucher I., Prevotat A., et al. (2021). Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease. Am. J. Respir. Crit. Care Med. 204 (1), 64–73. 10.1164/rccm.202011-4153OC PubMed DOI

Cystic Fibrosis Foundation (2022). Cystic fibrosis foundation patient registry 2021 annual data report. Bethesda, Maryland: ©2022 Cystic Fibrosis Foundation. Available at: https://www.cff.org/medical-professionals/patient-registry (Accessed February 20, 2023).

Djavid A. R., Thompson A. E., Irace A. L., Gusman E., Altman K., DiMango E. A., et al. (2021). Efficacy of elexacaftor/tezacaftor/ivacaftor in advanced cystic fibrosis lung disease. Ann. Am. Thorac. Soc. 18 (11), 1924–1927. 10.1513/AnnalsATS.202102-220RL PubMed DOI

Elborn J. S. (2016). Cystic fibrosis. Lancet 388 (10059), 2519–2531. 10.1016/S0140-6736(16)00576-6 PubMed DOI

Girón Moreno R. M., García-Clemente M., Diab-Cáceres L., Martínez-Vergara A., Martínez-García M. Á., Gómez-Punter R. M. (2021). Treatment of pulmonary disease of cystic fibrosis: A comprehensive review. Antibiot. (Basel) 10 (5), 486. 10.3390/antibiotics10050486 PubMed DOI PMC

Goss C. H. (2019). Acute pulmonary exacerbations in cystic fibrosis. Semin. Respir. Crit. Care Med. 40 (6), 792–803. 10.1055/s-0039-1697975 PubMed DOI PMC

Heijerman H. G. M., McKone E. F., Downey D. G., Van Braeckel E., Rowe S. M., Tullis E., et al. (2019). Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial. Lancet 394 (1023/8), 1940–1948. 10.1016/S0140-6736(19)32597-8 PubMed DOI PMC

Middleton P. G., Mall M. A., Dřevínek P., Lands L. C., McKone E. F., Polineni D., et al. (2019). Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. N. Engl. J. Med. 381 (19), 1809–1819. 10.1056/NEJMoa1908639 PubMed DOI PMC

O'Shea K. M., O'Carroll O. M., Carroll C., Grogan B., Connolly A., O'Shaughnessy L., et al. (2021). Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease. Eur. Respir. J. 57 (2), 2003079. 10.1183/13993003.03079-2020 PubMed DOI

Orenti A., Zolin A., Jung A., van Rens J. (2022). ECFSPR annual report 2020. Available at: https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports (Accessed January 12, 2023).

Ramsey B. W., Davies J., McElvaney N. G., Tullis E., Bell S. C., Dřevínek P., et al. (2011). A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 365 (18), 1663–1672. 10.1056/NEJMoa1105185 PubMed DOI PMC

Rowe S. M., Daines C., Ringshausen F. C., Kerem E., Wilson J., Tullis E., et al. (2017). Tezacaftor-ivacaftor in residual-function heterozygotes with cystic fibrosis. N. Engl. J. Med. 377 (21), 2024–2035. 10.1056/NEJMoa1709847 PubMed DOI PMC

Taylor-Cousar J. L., Munck A., McKone E. F., van der Ent C. K., Moeller A., Simard C., et al. (2017). Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del. N. Engl. J. Med. 377 (21), 2013–2023. 10.1056/NEJMoa1709846 PubMed DOI

Wainwright C. E., Elborn J. S., Ramsey B. W., Marigowda G., Huang X., Cipolli M., et al. (2015). Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N. Engl. J. Med. 373 (3), 220–231. 10.1056/NEJMoa1409547 PubMed DOI PMC